Digirad Corporation Reports Fourth Quarter and Year-End Financial Results

SUWANEE, Ga., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Digirad Corporation (Nasdaq:DRAD) today reported fourth quarter earnings of $0.8 million, or $0.04 per diluted share, with total revenues of $12.5 million. Ending cash, cash equivalents and available-for-sale securities was $26.4 million.

Digirad President and CEO Matt Molchan said, "The financial results and the operational progress made by the organization in the fourth quarter continues to be right on track and illustrate how we can continue to generate profitability and cash from the business while implementing the framework and business discipline necessary to sustain growth for the future.

"In DIS, we added customers and leveraged our resources more efficiently, and as a result, increased our margins in our operating hubs. In Diagnostic Imaging, we increased margins on system sales during the period, and for all of Digirad, as expected, we generated cash flow from operations and profits. Along with our results for the fourth quarter, we also recently announced the termination of the lease of our former headquarters, a move we think will save between $400,000 to $500,000 annually, showing that we continue to look for meaningful ways to right-size our business and squeeze efficiency from it." Molchan added, "Our general expectation continues to be that we will be a net cash flow generator on an annual basis and will continue to deliver value back to shareholders via a growing business enterprise and a continued and sustainable dividend."

The Company previously announced on February 3, 2014 a dividend of $0.05 per share that was paid on February 24, 2014, to shareholders of record on February 14, 2014.

Fourth Quarter 2013 Summary

  • Total revenue for the fourth quarter of 2013 was $12.5 million, compared to $13.0 million for the same period in the prior year. DIS revenue for the fourth quarter of 2013 was $9.3 million, compared to $8.5 million for the same period of the prior year, and Diagnostic Imaging revenue for the fourth quarter of 2013 was $3.3 million, compared to $4.5 million for the same period of the prior year.
  • Gross profit for the fourth quarter of 2013 was $3.7 million, or 29.4% of revenue, compared to $2.6 million, or 20.1% of revenue in the prior year quarter.
  • Net income for the fourth quarter of 2013 was $0.8 million, or $0.04 net income per diluted share, compared to a net loss of $1.9 million, or $0.10 net loss per diluted share, in the same period of the prior year.
  • Operating expenses for the fourth quarter of 2013 were $2.9 million, compared to $4.5 million in the same period in the prior year.
  • Cash, cash equivalents and available-for-sale securities totaled $26.4 million as of December 31, 2013. Cash, cash equivalents and available-for-sale securities totaled $25.9 million at September 30, 2013 and $27.2 million as of December 31, 2012.

Full-Year 2013 Summary

  • Total revenue for 2013 was $49.4 million, compared to $50.5 million for the same period in the prior year. DIS revenue for 2013 was $37.2 million, compared to $36.1 million for the same period of the prior year. Diagnostic Imaging revenue for 2013 was $12.2 million, compared to $14.4 million for the same period of the prior year.
  • Gross profit for 2013 was $14.1 million, or 28.6% of revenue, compared to $13.1 million, or 25.9% of revenue in the same period of the prior year.
  • Net income for 2013 was $0.3 million, or $0.01 net income per diluted share, compared to a net loss of $4.9 million, or $0.26 net loss per diluted share, in the same period of the prior year. Adjusted net income for 2013, excluding expenses incurred for nonrecurring items related to restructuring activities and the gain on sale of assets and associated license agreement, was $0.4 million, or $0.02 adjusted net income per diluted share, compared to an adjusted net loss of $4.9 million, or $0.26 adjusted net loss per diluted share, for the same period in the prior year.
  • Operating expenses for 2013 were $13.9 million, compared to $18.2 million in the same period in the prior year. Adjusted operating expenses, excluding expenses incurred for nonrecurring items related to restructuring activities and the gain on sale of assets and associated license agreement, for 2013 were $13.8 million, compared to the $18.2 million in the same period of the prior year. In addition to the restructuring costs and the gain on sale of assets and associated license agreement, operating expenses for 2013 included approximately $0.7 million in costs related to the proxy contest and subsequent litigation with the dissident shareholder group that was settled earlier in the year.

Conference Call Information

A conference call is scheduled for 1:00 p.m. EST today to discuss the results and management's outlook. The call may be accessed by dialing 877-941-2321 five minutes prior to the scheduled start time and referencing Digirad. A simultaneous webcast of the call may be accessed online from the Events & Presentations link on the Investor Relations page at www.digirad.com; an archived replay of the webcast will be available within 15 minutes of the end of the conference call.

Use of Non-GAAP Financial Measures by Digirad Corporation

This Digirad news release presents the non-GAAP financial measures "adjusted operating expenses," "adjusted net income (loss)", "adjusted net income (loss) per diluted share" and "adjusted EBITDA". The most directly comparable measure for these non-GAAP financial measures are operating expenses, net income (loss) and diluted net income (loss) per share. The Company has included below unaudited adjusted financial information for the quarters and years ended December 31, 2013 and 2012, which present the Company's results of operations after excluding restructuring charges and gain on the sale of assets and license agreement, and in the measure of adjusted EBITDA, interest, taxes, depreciation, amortization and stock-based compensation.

A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding Digirad's financial condition and results of operations is included as Exhibit 99.2 to Digirad's report on Form 8-K filed with the Securities and Exchange Commission on February 26, 2014.

About Digirad Corporation

Digirad delivers convenient, effective, and efficient diagnostic imaging solutions on an as needed, when needed, and where needed basis. Digirad is one of the largest national providers of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers, and also sells medical diagnostic imaging systems for nuclear cardiology and general nuclear medicine applications. For more information, please visit www.digirad.com. Digirad® and Cardius® are registered trademarks of Digirad Corporation.

Forward-Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Some of these forward-looking statements can be identified by the use of forward-looking words such as "believes," "expects," "may," "will," "should," "seek," "approximately," "intends," "plans," "estimates," or "anticipates," or the negative of those words or other comparable terminology, or in specific statements such as the Company's ability to deliver value to customers, the ability to grow and generate positive cash flow, the ability to execute on restructuring activities, and ability to successfully execute acquisitions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. These risks are detailed in Digirad's filings with the U.S. Securities and Exchange Commission, including the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Digirad undertakes no obligation to revise or update the forward-looking statements contained herein.

(Financial tables follow)

Digirad Corporation
Consolidated Statements of Comprehensive Income (Loss)
(Unaudited)
Three Months Ended Year Ended
December 31, December 31,
(in thousands, except per share amounts) 2013 2012 2013 2012
Revenues:
DIS $ 9,268 $ 8,542 $ 37,171 $ 36,064
Diagnostic Imaging 3,259 4,475 12,205 14,449
Total revenues 12,527 13,017 49,376 50,513
Cost of revenues:
DIS 6,908 6,529 27,828 27,293
Diagnostic Imaging 1,931 3,878 7,432 10,128
Total cost of revenues 8,839 10,407 35,260 37,421
Gross profit 3,688 2,610 14,116 13,092
Total gross profit percentage 29.4% 20.1% 28.6% 25.9%
DIS gross profit percentage 25.5% 23.6% 25.1% 24.3%
Diagnostic Imaging gross profit percentage 40.7% 13.3% 39.1% 29.9%
Operating expenses:
Research and development 5 718 1,025 3,716
Marketing and sales 1,124 1,667 4,411 6,402
General and administrative 1,691 2,019 8,118 7,839
Amortization of intangible assets 53 49 231 233
Restructuring charges 35 1,728
Gain on sale of assets and license agreement (1,568)
Total operating expenses 2,908 4,453 13,945 18,190
Income (loss) from operations 780 (1,843) 171 (5,098)
Other income (expense):
Interest and other income, net 11 19 63 101
Interest expense (5) (1) (15) (4)
Total other income 6 18 48 97
Income (loss) before income taxes 786 (1,825) 219 (5,001)
Income tax benefit (expense) 1 (34) 45 77
Net income (loss) $ 787 $ (1,859) $ 264 $ (4,924)
Net income (loss) per share – basic $ 0.04 $ (0.10) $ 0.01 $ (0.26)
Net income (loss) per share – diluted $ 0.04 $ (0.10) $ 0.01 $ (0.26)
Weighted average shares outstanding – basic 18,491 19,276 18,789 19,274
Weighted average shares outstanding – diluted 18,803 19,276 19,159 19,274
DIGIRAD CORPORATION
CONSOLIDATED BALANCE SHEETS
(Unaudited)
As of December 31,
(in thousands) 2013 2012
Assets
Current assets:
Cash and cash equivalents $ 18,744 $ 19,514
Securities available-for-sale 7,673 7,679
Accounts receivable, net 5,430 6,329
Inventories, net 3,881 4,979
Other current assets 697 642
Restricted cash 244 244
Total current assets 36,669 39,387
Property and equipment, net 4,153 4,693
Intangible assets, net 353 584
Goodwill 184 184
Other assets 92 61
Total assets $ 41,451 $ 44,909
Liabilities
Current liabilities:
Accounts payable $ 611 $ 1,546
Accrued compensation 3,472 2,364
Accrued warranty 137 326
Deferred revenue 1,631 1,849
Other accrued liabilities 1,774 2,199
Total current liabilities 7,625 8,284
Other liabilities 440 176
Total liabilities 8,065 8,460
Stockholders' equity:
Preferred stock
Common stock 2 2
Treasury stock (5,728) (2,086)
Additional paid-in capital 156,968 156,634
Accumulated other comprehensive income (loss) (2) 17
Accumulated deficit (117,854) (118,118)
Total stockholders' equity 33,386 36,449
Total liabilities and stockholders' equity $ 41,451 $ 44,909
Digirad Corporation
Reconciliation of Non-GAAP Financial Measures
(Unaudited)
Three Months Ended December 31, Year Ended December 31,
(in thousands, except per share amounts) 2013 2012 2013 2012
Total operating expenses $ 2,908 $ 4,453 $ 13,945 $ 18,190
Restructuring charges(1) (35) (1,728)
Gain on sale of assets and license agreement(2) 1,568
Non-GAAP Adjusted operating expenses $ 2,873 $ 4,453 $ 13,785 $ 18,190
Net income (loss) $ 787 $ (1,859) $ 264 $ (4,924)
Restructuring charges(1) 35 1,728
Gain on sale of assets and license agreement(2) (1,568)
Income tax items(3)
Non-GAAP Adjusted net income (loss) $ 822 $ (1,859) $ 424 $ (4,924)
Net income (loss) per share - diluted $ 0.04 $ (0.10) $ 0.01 $ (0.26)
Restructuring charges(1)(4) 0.09
Gain on sale of assets and license agreement(2)(4) (0.08)
Income tax items(3)(4)
Non-GAAP Adjusted net income (loss) per share - diluted(4) $ 0.04 $ (0.10) $ 0.02 $ (0.26)
Three Months Ended December 31, Year Ended December 31,
(in thousands) 2013 2012 2013 2012
Net income (loss) $ 787 $ (1,859) $ 264 $ (4,924)
Restructuring charges(1) 35 1,728
Gain on sale of assets and license agreement(2) (1,568)
Depreciation and amortization 466 481 1,913 2,131
Stock-based compensation 40 159 340 630
Interest and other income, net (11) (19) (63) (101)
Interest expense 5 1 15 4
Income tax (benefit) expense (1) 34 (45) (77)
Non-GAAP Adjusted EBITDA $ 1,321 $ (1,203) $ 2,584 $ (2,337)
(1) Reflects nonrecurring charges primarily related to restructuring of the Diagnostic Imaging reporting segment.
(2) Reflects a nonrecurring gain related to the sale of assets associated with an uncommercialized surgical imaging system, and the licensing of certain existing Company technology.
(3) Reflects income tax effect for adjusted financial data.
(4) Per share amounts are computed independently for each discrete item presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal to the total for the year.
Digirad Corporation
Reconciliation of Non-GAAP Financial Measures
(Unaudited)
Three Months Ended
(in thousands, except per share amounts) March 31, 2013 June 30, 2013 September 30, 2013 December 31, 2013
Total operating expenses $ 5,226 $ 4,425 $ 1,386 $ 2,908
Restructuring charges(1) (1,004) (610) (79) (35)
Gain on sale of assets and license agreement(2) 1,568
Non-GAAP Adjusted operating expenses $ 4,222 $ 3,815 $ 2,875 $ 2,873
Net income (loss) $ (2,419) $ (616) $ 2,512 $ 787
Restructuring charges(1) 1,004 610 79 35
Gain on sale of assets and license agreement(2) (1,568)
Income tax items(3)
Non-GAAP Adjusted net income (loss) $ (1,415) $ (6) $ 1,023 $ 822
Net income (loss) per share - diluted(4) $ (0.13) $ (0.03) $ 0.14 $ 0.04
Restructuring charges(1)(4) 0.06 0.03
Gain on sale of assets and license agreement(2)(4) (0.08)
Income tax items(3)(4)
Non-GAAP Adjusted net income (loss) per share - diluted(4) $ (0.07) $ — $ 0.06 $ 0.04
Three Months Ended
(in thousands) March 31, 2013 June 30, 2013 September 30, 2013 December 31, 2013
Net income (loss) $ (2,419) $ (616) $ 2,512 $ 787
Restructuring charges(1) 1,004 610 79 35
Gain on sale of assets and license agreement(2) (1,568)
Depreciation and Amortization 493 479 475 466
Stock-based Compensation 121 105 74 40
Interest and other income, net (23) (16) (13) (11)
Interest expense 1 4 5 5
Income tax benefit (expense) 32 (4) (72) (1)
Non-GAAP Adjusted EBITDA $ (791) $ 562 $ 1,492 $ 1,321
(1) Reflects nonrecurring charges primarily related to restructuring of the Diagnostic Imaging reporting segment.
(2) Reflects a nonrecurring gain related to the sale of assets associated with an uncommercialized surgical imaging system, and the licensing of certain existing Company technology.
(3) Reflects income tax effect for adjusted financial data.
(4) Per share amounts are computed independently for each discrete item presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal to the total for the year.

CONTACT: For more information contact: Jeffry Keyes Chief Financial Officer 858-726-1600 ir@digirad.com

Source:Digirad Corporation